View of orthopedist-traumatologist on the possibility of using teriparatide in patients with osteoporotic bone fractures


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The review article presents a systematic information about the mechanisms of action and efficacy of synthetic human parathyroid hormone апаlogгу - teriparatide - in men and women with osteoporotic bone fractures. The results of experimental and clinical studies have confirmed the anabolic effect of this drug on bone metabolism, as well as its ability to increase bone mineral density (BMD) and reduce the risk of recurrent osteoporotic fractures, even in patients with very low BMD and several previous low-energy bone fractures. Literature data for the positive effects of teriparatide therapy on the processes of reparative regeneration of bone after fractures are separately analyzed. As a result, it is concluded that this drug has a particular importance for the examined cohort of patients usually treated by orthopedist-traumatologist, since it is able to simultaneously optimize the existing processes of bone union and to prevent repeated bone fractures in patients with osteoporosis.

Full Text

Restricted Access

References

  1. Лесняк О.М. Аудит состояния проблемы остеопороза в странах Восточной Европы и Центральной Азии-2010. Остеопороз и остеопатии. 2011;2:3-6.
  2. Михайлов Е.Е., Беневоленская Л.И., Баркова Т.В. Эпидемиологическая характеристика переломов костей конечностей в популяционной выборке лиц 50 лет и старше. Остеопороз и остеопатии.1998;2:2-6.
  3. Лесняк О.М., Ершова О.Б. Аудит состояния проблемы остеопороза в странах Восточной Европы и Центральной Азии-2010: Российская Федерация. Издание международного Фонда остеопороза. 2011. С. 46-52.
  4. Лесняк О.М. Современная модель оказания медицинской помощи при остеопорозе, основанная на вторичной профилактике переломов. Эффективная фармакотерапия. 2013;34:34-9.
  5. Кочиш А.Ю., Лесняк О.М., Иванов С.Н., Силиди И.Ю. Первый опыт организации в Санкт-Петербурге вторичной профилактики повторных остеопоротических переломов костей в рамках программы «Прометей» Российской ассоциации по остеопорозу. Фарматека. 2014;S5:12-7.
  6. Лесняк О.М. Российский экспертный совет по применению инновационного препарата анаболического действия Форстео (терипаратид) в лечении тяжелого остеопороза. Современная ревматология. 2013;3:76-8.
  7. Кочиш А.Ю., Мироненко А.Н., Ласунский С.А., Стафеев Д.В. Возможности фармакологической коррекции постменопаузального остеопороза у пациенток с внесуставными переломами проксимального отдела бедренной кости. Травматология и ортопедия России. 2011;2:50-6.
  8. Пигарова Е.А., Рожинская Л.Я. Применение терипаратида для лечения тяжелого остеопороза с множественными переломами. Остеопороз и остеопатии. 2014;1:38-42.
  9. Кочиш А.Ю., Иванов С.Н., Стафеев Д.В., Минасов Т.Б. Возможности и перспективы использования препаратов двойного действия для фармакотерапии системного остеопороза у пациентов с переломами костей. Травматология и ортопедия России. 2012;2:99-104.
  10. Белая Ж.Е., Рожинская Л.Я. Анаболическая терапия остеопороза. Терипаратид: эффективность, безопасность и область применения. Остеопороз и остеопатии. 2013;2:32-40.
  11. European Medicines Agency recommends to restrict that Protelos/Osseor remain available but with further restrictions. 21 February 2013 EMA/84749/2014.
  12. Habener J.F., Potts J.T. Biosynthesis of parathyroid hormone (Part 1). New England. J. Medicine. 1978;299:580-85.
  13. Potts J.T., Bringhurst F.R., Gardella Т. Parathyroid hormone: physiology, chemistry, biosynthesis, secretion, metabolism and mode of action. In: DeGroot L.J., Ed. Endocrinology 3rd edn. Philadelphia: WB Saunders. 1995;2:920-66.
  14. Potts J.T. The non-traditional actions of parathyroid hormone: status 1991, an overview. J. Endocrinology Investigation. 1992;15:3-9.
  15. Jin L., Briggs S.L., Chandrasekhar S., Chirgadze N.Y., Clawson D.K., Schevitz R.W., Smiley D.L., Tashjian A.H., Zhang F. Crystal structure of human parathyroid hormone 1-34 at 0.9-A Resolution. J. Biological. Chemistry. 2000;275:27238-44.
  16. Rubin M.R., Cosman F., Lindsay R., Bilezikian J.P. The anabolic effects of parathyroid hormone. Osteoporos. Int. 2002;13:267-77.
  17. Health D. Familial hypocalcemia - not hypo parathyroidism. New England J. Medicine. 1996;335:1144-45.
  18. Dempster D.W., Parisien M., Silverberg S.J., Liang X.G., Schnitzer M., Shen V., Shane E., Kimmel D.B., Recker R., Lindsay R., Bilezikian J.P. On the mechanism of cancellous bone preservation in postmenopausal women with mildprimary hyperpa-rathyroidism. J. Clin. Endocrinology Metabolism. 1999;84:1562-66.
  19. Sato M., Miyauchi A., Takahara J. Clinical aspects of hyperparathyroidism in Japanese multiple endocrine neoplasia type 1. J. Biomedecine and Pharmacotherapy. 2000;54(Suppl. 1):86s-89s.
  20. Dobnig H., Turner R.T. Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult by activation of bone lining cells. J. Endocrinology. 1995; 136:3632-38.
  21. Onyia J.E., Bidwell J., Herring I., Hulman J., Hock J.M. In vivo human parathyroid hormone fragment (hPTH 1-34) transiently stimulates immediate early response gene expression, but not proliferation in trabecular bone cells of young rats. J. Bone. 1995;17:479-84.
  22. Schmidt I.U., Dobing H., Turner R.T. Intermittent parathyroid hormone treatment increases osteoblast number, steady state messenger ribonucleic acid levels for osteocalcin, and bone formation in tibial metaphysis of hypophysectomized female rats. J. Endocrinology. 1995; 136:5127-34.
  23. Neer R.M., Arnaud C.D., Zanchetta J.R., Prince R., Gaich G.A., Reginster J.Y., Hodsman A.B., Eriksen E.F., Ish-Shalom S., Genant H.K., Wang O., Mitlak B.H. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. New Engl. J. Med. 2001;344(19):1434-41.
  24. Kaufman J.M., Orwoll E., Goemaere S., San Martin J., Hossain A., Dalsky G.P., Lindsay R., Mitlak B.H. Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. Osteoporos. Int. 2005;16:510-16.
  25. Draper M.W., Flowers D.E, Huster W.J., Neild J.A., Harper K.D., Arnaud C. A controlled trial of raloxifene (LY139481) HC1: impact on bone turnover and serum lipid profile in healthy post-menopausal women. J. Bone Mineral. Research. 1996;11:835-42.
  26. Nevitt M.C., Chen P., Dore R.K., Reginster J.Y., Kiel D.P., Zanchetta J.R., Glass E.V., Krege J.H. Reduced risk of back pain following teriparatide treatment: a meta-analysis. Osteoporos. Int. 2006;17:1630-73.
  27. Miller P.O., Bilezikian J.P., Deal C., Harris S.T., Ci R.P. Clinical use of teriparatide in the real world: initial insights. J. Endocrine Practice. 2004;10:139-48.
  28. Krohn K., Valenzuela G., Lane J.M., et al. Влияние наличия перелома бедра в анамнезе на эффективность терипаратида у пациентов с остеопорозом. Проблема остеопороза в травматологии и ортопедии. Тез. докл. VI Конф. с международным участием. М., 2015;34-5.
  29. Rehman Q., Lang T.F., Arnaud C.D., Modin G.W., Lane N.E. Daily treatment with parathyroid hormone is associated with an increase in vertebral cross-sectional area in postmenopausal women with glucocorticoid-induced osteoporosis. Osteoporos. Int. 2003;14:77-81.
  30. Rittmaster R.S., Bolognese M., Ettinger M.P., Hanley D.A., Hodsman A.B., Kendler D.L., Rosen C.J. Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J. Clin. Endocrinol. Metab. 2000;85:2129-34.
  31. Black D.M., Greenspan S.L., Ensrud K.I., Palermo L., McGowan J.A., Lang T.F., Garnero P., Bouxsein M.L., Bilezikian J.P., Rosen C.J.; PaTH Study Investigators. The effects of Parathyroid hormone and Alendronate alone or in combination in postmenopausal osteoporosis. The New England J. Medicine. 2003;349: 1207-15.
  32. Finkelstein J.S., Hayes A., Hunzelman J.L., Wyland J.J., Lee H., Neer R.M. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. The New England J. Medicine. 2003;349:1216-26.
  33. Alkhiary Y.M., Gerstenfeld L.C., Krall E., Westmore M., Sato M., Mitlak B.H., Einhorn T.A. Enhancement of experimental fracture-healing by systemic administration of recombinant human parathyroid hormone (PTH 1-34). J. Bone Joint Surg. Am. 2005;87(4):731-41.
  34. Chalidis B., Tzioupis C., Tsiridis E., Giannoudis P.V. Enhancement of fracture healing with parathyroid hormone: preclinical studies and potential clinical applications. Expert Opin. Investig. Drugs. 2007;16(4):441-49.
  35. Cipriano C.A., Issack P.S., Shindle L., Werner C.M., Helfet D.L., Lane J.M. Recent advances toward the clinical application of PTH (1-34) in fracture healing. HSS J. 2009;5(2):149-53.
  36. Manabe T., Mori S., Mashiba T., Kaji Y., Iwata K., Komatsubara S., Seki A., Sun Y.X., Yamamoto T. Human parathyroid hormone (1-34) accelerates natural fracture healing process in the femoral osteotomy model of cynomolgus monkeys. Bone. 2007;40(6):1475-82.
  37. Aspenberg P.,Genant H.K., JohanssonT., Nino A.J., See K., Krohn K., Garcia-Hernandez P.A., Recknor C.P., Einhorn T.A., Dalsky G.P., Mitlak B.H., Fierlinger A., Lakshmanan M.C. Teriparatide for acceleration of fracture repair in humans: a prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures. J. Bone Miner. Res. 2010;25(2):404-14.
  38. Bukata S.V., Kaback L.A., Reynolds D.G., O'Keefe R.J., Rosier R.N. University of Rochester, Rochester, NY 1-34 PTH at physiologic doses in humans shows promise as a helpful adjuvant in difficult to heal fractures: an observational cohort of 145 patient. Presented as a paper at the Orthopaedic Research Society 55th Annual Meeting: February 25-28. Las Vegas, 2009.
  39. Yu C-T., Wu J-K., Chang C-C., Chen C.L., Wei J.C. Early callus formation in human hip fracture treated with internal fixation and teriparatide [letter to the editor]. J. Rheumatol. 2008;35(1):2082-83.
  40. Borges J.L.C., Freitas A., Bilezikian J.P. Accelerating fracture healing with teriparatide. Arq. Bras. Endocrinol. Metab. 2013;57(2): 153-56.
  41. Raghavan P., Christofides E. Role jf teriparatide in accelerating metatarsal stress fracture healing: A case series and review of literature. Clinical Med. Insights Endocrinol. Diabetes. 2012;5:39-45.
  42. Chintamaneni S., Finzel K., Gruber B.L. Successful treatment of sternal fracture nonunion with teriparatide. Osteoporos. Int. 2010;21(6):1059-63.
  43. Carvalho N.N., Voss L.A., Almeida M.O., Salgado C.L., Bandeira F. Atypical femoral fractures during prolonged use of bisphosphonates: short-term responses to strontium ranelate and teriparatide. J. Clin. Endocrinol. Metab. 2011;96(9):2675-80.
  44. Gomberg S.J., Wustrack R.L., Napoli N., Arnaud C.D., Black D.M. Teriparatide, vitamin D, and calcium healed bilateral subtrochanteric stress fractures in a postmenopausal woman with a 13-year history of continuous alendronate therapy. J. Clin. Endocrinol. Metab. 2011;96(9):1627-32.
  45. Unnanuntana A., Saleh A., Menash K.A., Kleimeyer J.P., Lane J.M. Atypical femoral fractures: What do we know about them? J. Bone Joint Surg. Am. 2013;95(2):1-13.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies